Compare NextEra Energy, Inc. (NEE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Viatris Inc — how do they compare? NextEra Energy, Inc. trades at $77.44 (market cap $161.39B), while Viatris Inc trades at $17.71 (market cap $20.03B). The key difference: NextEra Energy, Inc. is far larger — about 8.1× Viatris Inc's market cap, and NextEra Energy, Inc. pays the higher dividend (3.22%). Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and Viatris Inc for 57 Days on average.
| NEE | VTRS | |
|---|---|---|
Market Cap | $161.39B | $20.03B |
Volume | 11,780,955 | 14,109,977 |
Sector | Utilities | Health |
52-Week High | $97.88 | $18.27 |
52-Week Low | $75.49 | $9.74 |
Typical Hold Time | 83 Days | 57 Days |
Enterprise Value | $268.72B | $32.15B |
Dividend Yield | 3.22% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $77.34, up 0.36% on the day, with a bearish technical signal but strong analyst support. The stock is near a 52-week low, with key support at $76. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains robust profitability with a 32.4% net margin and is pursuing growth through projects like the $22.3 billion Project Star energy campus.
The outlook is cautiously optimistic, with a consensus price target of $96 offering 24% upside. Risks include high debt levels and interest rate sensitivity, but strong cash flow and a 66.7% buy rating from analysts suggest long-term value. Investors should weigh growth initiatives against macroeconomic headwinds.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
